FDA Approval Treasure Hunters

[Rawnoc]

REPR -- profitable, cash-rich, rapidly growing, recession-proof, tiny float OS & market cap with a juicy FDA approval pending any week...

Management is so confident of continued much higher profits than last quarter going forward that they have set aside a "deferred tax asset" in the balance sheet "based the valuation allowance calculations on the prospect of future profitability"
http://pinksheets.com/edgar/GetFilingHtml?FilingID=6632631

Products are recession-proof with no direct competition with sales rapidly expanding due to a new treatment (Vivaglobin) where their infusion pump is the best, cheapest, safest, and most convenient form of delivery:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=28775119
http://investorshub.advfn.com/boards/read_msg.asp?message_id=28777209
http://investorshub.advfn.com/boards/read_msg.asp?message_id=28838178

Medicare reimbursement for the Freedom60 (their biggest & most exciting revenue-generating product) was increased 20 fold in June of 2007 and is the ONLY infusion pump accepted by Medicare for reimbursement for Subcutaneous Immune Globulin treatment (Vivaglobin):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=28776642
http://investorshub.advfn.com/boards/read_msg.asp?message_id=28776847

They are hiring like crazy:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39063328
http://www.rmsmedicalproducts.com/Careers.htm

FDA Approval pending and could be announced any day which should help accelerate sales & earnings:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38239770

Based on seasonal & cylical patterns as well as their recent hiring and doubling of shifts and landing business with a huge hospital & the pending FDA approval, I suspect REPR is 1 or 2 quarters away from +.02 EPS per quarter or more or an annualized +.08 EPS pace IMO. 10 PE = .80/share, 15 PE = $1.20/share. 20 PE = $1.80/share

REPR Board:
http://investorshub.advfn.com/boards/board.aspx?board_id=201